Jia (Jenny) Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, Conjoint Associate Professor at UNSW, shared a post on X:
“Insightful talk by Naoto T Ueno ASCOBT26 Breast ADCs: earlier lines, HER2-low/ultralow expansion, rational IO/DDR combinations, resistance biology, PROs and sequencing.
The science is accelerating but biomarker selection and equitable access must keep pace.”
More posts about ASCOBT26.
